Pharma Major Lupin has launched Abacavir and Lamivudine tablets, 600 mg/300 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier.

The company’s Abacavir and Lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare Company's Epzicom tablets, 600 mg/300 mg.

It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Epzicom tablets had US sales of $388.1 million according to IMS MAT December 2016.

Shares of the company gained Rs 2, or 0.14%, to trade at Rs 1,458.50. The total volume of shares traded was 35,631 at the BSE (12.46 p.m., Wednesday).